ZEB2 and colorectal carcinoma: In agreement with our hypothesis that ZEB2 drives an EMT-related and therapy-resistant CRC phenotype we found a significantly increased expression of ZEB2 in CMS4 (***P < 0.001, n = 2822) (Fig. 5b).